Literature DB >> 11905803

Improving the efficacy of antibody-based cancer therapies.

P Carter1.   

Abstract

A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11905803     DOI： 10.1038/35101072

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  150 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide.

Authors:  Jennifer S Andrew; Emily J Anglin; Elizabeth C Wu; Michelle Y Chen; Lingyun Cheng; William R Freeman; Michael J Sailor
Journal:  Adv Funct Mater       Date:  2010-09-08       Impact factor: 18.808

Review 3.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

4.  Modeling the three-dimensional structures of an unbound single-chain variable fragment (scFv) and its hypothetical complex with a Corynespora cassiicola toxin, cassiicolin.

Authors:  Adeel Malik; Ahmad Firoz; Vivekanand Jha; Elumalai Sunderasan; Shandar Ahmad
Journal:  J Mol Model       Date:  2010-03-16       Impact factor: 1.810

5.  Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.

Authors:  Chan Hyuk Kim; Jun Y Axup; Anna Dubrovska; Stephanie A Kazane; Benjamin A Hutchins; Erik D Wold; Vaughn V Smider; Peter G Schultz
Journal:  J Am Chem Soc       Date:  2012-06-06       Impact factor: 15.419

6.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

Review 7.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

8.  Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment.

Authors:  Laurent Gros; Hanna Dreja; Anne Laure Fiser; Marc Plays; Mireia Pelegrin; Marc Piechaczyk
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 9.  FLT3 antibody-based therapeutics for leukemia therapy.

Authors:  Yiwen Li; Zhenping Zhu
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

10.  Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.

Authors:  Hyuk-Joon Lee; Hye Seung Lee; Keun Hur; Woo Ho Kim; Kazuyoshi Yanagihara; Karl-Friedrich Becker; Kuhn Uk Lee; Han-Kwang Yang
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-19       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.